AKT1 and lung carcinoma: The SM may exert its anti‐lung cancer activity by dose‐dependently down‐regulates Protein kinase B (AKT/PKB) phosphorylation, SP1, NF‐κB subunit p65, and E‐prostanoid receptor 4 (EP4) in lung cancer cell lines (A549 and H1299 cells).58